Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomecompanyTiblone
Tiblone
Tiblone

Tiblone

Price USD1.00
Packge 1g
  • Min. Order:1g
  • Supply Ability:20000kg
  • Time:2019-07-31

Product Details

  • Product NameTiblone
  • CAS No.5630-53-5
  • EINECS No.227-069-1
  • MFC21H28O2
  • MW312.45
  • Appearanceneatwhite to beige
  • Melting point 169 °C
  • storage temp. 2-8°C
  • Boiling point 447.4±45.0 °C(Predicted)
  • density 1.13±0.1 g/cm3(Predicted)

Product name: Tiblone 
Synonyms: Lial,Liviella
CAS No: 5630 53 5
EINECS:227-069-1
Molecular Formula: C26H34O4 
Molecular Weight:312.45
Assay: 97.0%~103.0% 
Appearance: White or off-white crystalline powder 
Usage: Can be used as pharmaceutical material, It is a synthetic hormone-type drug which is used mainly for hormone replacement therapy in post-menopausal women. 
Grade: Pharmaceutical Grade 

Tiblone Lial/Liviella is used mainly for treatment of endometriosis, as well as hormone replacement therapy in post-menopausal women. Tiblone is a synthetic steid hormone drug, which is fairly non-selective in its binding profile, acting as an agonist mainly at estrogen receptors, with a preference for ER alpha. Tiblone has similar or greater efficacy compared to older hormone replacement drugs, but shares a similar side effect profile. It has also been investigated as a possible treatment for female sexual dysfunction. 

Tiblone is a synthetic hormone-type drug which is used mainly for hormone replacement therapy in post-menopausal women. It is a synthetic steid that has the same activity as the female sex hormones estrogen and progesterone and the androgen teststeone. Tiblone helps restore hormonal balance in the body. 

Company Profile Introduction

Recommended supplier

  • Since:2014-05-13
  • Address: Room 2004, Oriental Century Square Tower A, East Road Yellow River, Xinhua District, Cangzhou City
INQUIRY